Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil

[1]  M. Fukushima,et al.  Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo , 2004, Cancer Chemotherapy and Pharmacology.

[2]  D. Kerr,et al.  Immune enhancement of nitroreductase‐induced cytotoxicity: Studies using a bicistronic adenovirus vector , 2003, International journal of cancer.

[3]  D. Kerr,et al.  Induction of apoptosis by chemotherapeutic drugs: the role of FADD in activation of caspase-8 and synergy with death receptor ligands in ovarian carcinoma cells , 2002, Cell Death and Differentiation.

[4]  D. Kerr,et al.  Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  Cun-Yu Wang,et al.  Nuclear Factor-κB-inducible Death Effector Domain-containing Protein Suppresses Tumor Necrosis Factor-mediated Apoptosis by Inhibiting Caspase-8 Activity* , 2001, The Journal of Biological Chemistry.

[6]  Y. Lazebnik,et al.  Deficiency in caspase-9 or caspase-3 induces compensatory caspase activation , 2000, Nature Medicine.

[7]  I. Tannock,et al.  A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer , 2000, Nature Medicine.

[8]  D. Kerr,et al.  Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector‐mediated expression of E. coli nitroreductase , 2000, International journal of cancer.

[9]  D. Kerr,et al.  Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954 , 2000, Cancer Gene Therapy.

[10]  R. Steinman,et al.  The Induction of Tolerance by Dendritic Cells That Have Captured Apoptotic Cells , 2000, The Journal of experimental medicine.

[11]  S. Fulda,et al.  Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells. , 2000, Blood.

[12]  A. Melcher,et al.  Apoptosis or necrosis for tumor immunotherapy: what's in a name? , 1999, Journal of Molecular Medicine.

[13]  A. López-Rivas,et al.  p53-mediated up-regulation of CD95 is not involved in genotoxic drug-induced apoptosis of human breast tumor cells , 1999, Cell Death and Differentiation.

[14]  M MacFarlane,et al.  Distinct Caspase Cascades Are Initiated in Receptor-mediated and Chemical-induced Apoptosis* , 1999, The Journal of Biological Chemistry.

[15]  M. Peter,et al.  Activation of the CD95 (APO-1/Fas) pathway in drug- and γ-irradiation-induced apoptosis of brain tumor cells , 1998, Cell Death and Differentiation.

[16]  C. Y. Wang,et al.  NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. , 1998, Science.

[17]  N. D’alessandro,et al.  The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis , 1998, Cell Death and Differentiation.

[18]  I. McNeish,et al.  Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954 , 1998, Gene Therapy.

[19]  S. Fulda,et al.  Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system , 1998, International journal of cancer.

[20]  M. Martínez-Lorenzo,et al.  Doxorubicin‐induced apoptosis in human T‐cell leukemia is mediated by caspase‐3 activation in a Fas‐independent way , 1997, FEBS letters.

[21]  G. Schuurhuis,et al.  The Pgp specific combination Syto-R16/PSC833 detects early apoptosis in CD34 positive progenitor cells , 1997 .

[22]  I. Herr,et al.  The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. , 1997, Cancer research.

[23]  R. Greil,et al.  Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. , 1997, Cancer research.

[24]  W. Earnshaw,et al.  Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. , 1997, Blood.

[25]  E. Solary,et al.  Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. , 1997, Journal of the National Cancer Institute.

[26]  C. Link,et al.  Gene therapy for colon cancer with the herpes simplex thymidine kinase gene , 1997, Journal of surgical oncology.

[27]  I. Herr,et al.  Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells , 1996, Nature Medicine.

[28]  C. Springer,et al.  Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. , 1995, European journal of cancer.

[29]  B. Kramer,et al.  Combination cytotoxic effects of cis-diamminedichloroplatinum(II) and 5-fluorouracil with and without leucovorin against human non-small cell lung cancer cell lines. , 1993, Cancer research.

[30]  G. Wilkinson,et al.  Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector. , 1992, Nucleic acids research.

[31]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.